REG - Alliance Pharma PLC - Grant of Options to Directors

Alliance PharmaAnnouncement

05/10/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231005:nRSE8801Oa&default-theme=true

RNS Number : 8801O  Alliance Pharma PLC  05 October 2023

 For immediate release  5 October 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that the Board has issued options over an aggregate of 2,281,643 ordinary
shares of 1 pence each in the Company, on the recommendation of the Company's
Remuneration Committee, to the PDMRs detailed below, pursuant to the Company's
Long-Term Incentive Plan 2019.

Peter Butterfield, Chief Executive Officer, has been awarded 851,666 share
options.

Andrew Franklin, Chief Financial Officer, has been awarded 568,866 share
options.

Jeyan Heper, Chief Operating Officer, has been awarded 861,111 share options
(250,000 of which have been awarded pursuant to his joining of the Company
earlier this year).

The awards have been granted at nil-cost and become exercisable on 4 October
2026 subject always to continued employment and the satisfaction of
performance conditions based on EPS, TSR and ROCE targets.

The net effect of the grant of Share Options and the resultant option holdings
are shown in the table below:

 Name               Share Options granted  Total no. of options over ordinary shares now held
 Peter Butterfield  851,666                4,057,553
 Andrew Franklin    568,866                2,845,373
 Jeyan Heper        861,111                861,111

 

The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

 

 

 

 

Notification and public disclosure of transactions by person discharging
managerial responsibilities.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Mr Peter Butterfield
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer - PDMR
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Alliance Pharma plc
 b)  Legal Entity Identifier                                      N/A
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1.0 pence each

     Identification code

                                                                  ISIN: GB0031030819
 b)  Nature of the transaction                                    Grant of Options
 c)  Currency                                                     GBP
 d)  Price(s) and volume(s)                                       Exercise Price (p)                     No. of share options
     Nil                                                                                                 851,666

 e)  Aggregated information                                       Grant of 851,666  options to acquire ordinary shares of 1 pence each at

                                                            nil-cost.
     - Aggregated volume

     - Price

     - Aggregated total

 f)  Date of the transaction                                      4 October 2023
 g)  Place of the transaction                                     Outside of trading venue

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Mr Andrew Franklin
 2   Reason for the notification
 a)  Position/status                                              Chief Financial Officer - PDMR
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Alliance Pharma plc
 b)  Legal Entity Identifier                                      N/A
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1.0 pence each

     Identification code

                                                                  ISIN: GB0031030819
 b)  Nature of the transaction                                    Grant of Options
 c)  Currency                                                     GBP
 d)  Price(s) and volume(s)                                       Exercise Price (p)                    No. of share options
     Nil                                                                                                568,866

 e)  Aggregated information                                       Grant of 568,866 options to acquire ordinary shares of 1 pence each at

                                                            nil-cost.
     - Aggregated volume

     - Price

     - Aggregated total
 f)  Date of the transaction                                       4 October 2023
 g)  Place of the transaction                                     Outside of trading venue

 

 

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Mr Jeyan Heper
 2   Reason for the notification
 a)  Position/status                                              Chief Operating Officer - PDMR
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Alliance Pharma plc
 b)  Legal Entity Identifier                                      N/A
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1.0 pence each

     Identification code

                                                                  ISIN: GB0031030819
 b)  Nature of the transaction                                    Grant of Options
 c)  Currency                                                     GBP
 d)  Price(s) and volume(s)                                       Exercise Price (p)                   No. of share options
     Nil                                                                                               861,111

 e)  Aggregated information                                       Grant of 861,111options to acquire ordinary shares of 1 pence each at

                                                            nil-cost.
     - Aggregated volume

     - Price

     - Aggregated total
 f)  Date of the transaction                                       4 October 2023
 g)  Place of the transaction                                     Outside of trading venue

 

 

 

 

 

For further information:

 

 Alliance Pharma plc                                                     + 44 (0)1249 466966
 Head of Investor Relations: Cora McCallum                               + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited (Nominated Adviser and Joint Broker)           + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                        + 44 (0)20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands. For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPGMWUUPWGAA